Weekly Cisplatin-Based Chemoradiotherapy Improves RFS and OS, Although Not Statistically Significant, for Patients with Cervical Cancer and Intermediate Pathologic Risk Factors By Ogkologos - September 24, 2025 212 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the NRG Oncology/GOG-263/KGOG1008 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Strong Independent Association of TILs with OS for Patients with ERBB2-positive... February 26, 2025 Withdrawal of the Application to Change the EMA Marketing Authorisation for... December 2, 2022 EMA Recommends Additional Extensions of Indications for Pembrolizumab October 7, 2024 Building a Balanced Breakfast November 6, 2020 Load more HOT NEWS Reflecting On My Time As the Cancer.Net Editor in Chief John Cena Set The Record For Most Make-A-Wish Visits And He... EMA Recommends Extension of Indications for Nivolumab to Include First-Line Treatment... Study Probes Awareness of Alcohol’s Link to Cancer
